Vivos Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Update
Vivos Therapeutics reported Q2 2026 revenue of $5.2 million, up 35% year-over-year, driven by strong service revenue from sleep testing and treatment operations. Gross margin improved to 57%, and the operating loss remained flat at $4.9 million despite the revenue growth, indicating improved operational efficiency.
Key figures
- Revenue
- 5153000
- Revenue Yoy
- 35%
- Gross margin
- 57%
- Gross profit
- 2953000
- Cash and equivalents
- 1774000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.